Jenifer Prosperi

Jenifer Prosperi is an Adjunct Associate Professor in the Department of Biological Sciences at the University of Notre Dame and an Associate Professor in the Department of Biochemistry and Molecular Biology at Indiana University School of Medicine. Her research is focused on the tumor suppressor gene APC and its role in breast cancer development, epithelial polarity, and chemotherapy resistance.

Her primary research areas include Cancer and Cellular & Molecular Biology, with specialties in breast cancer, chemoresistance, cell signaling, and three-dimensional morphogenesis. She investigates how APC loss leads to activation of pathways such as FAK, Src, and STAT3, contributing to tumor progression and resistance to treatment.

Dr. Prosperi's recent publications reveal a strong trend in understanding the molecular mechanisms of chemoresistance, particularly through APC loss and its downstream effects on drug efflux, DNA repair, and survival signaling. Her work bridges basic science with therapeutic applications, exploring combination therapies and novel targets in breast cancer.

Her scientific contributions have been recognized through numerous peer-reviewed publications in high-impact journals such as BMC Cancer, PLoS ONE, and Current Drug Targets. While specific awards are not listed, her sustained research output and leadership in the field underscore her scholarly impact.

She has advised multiple graduate students and postdoctoral researchers, contributing to training the next generation of scientists. Her lab employs both in vitro and in vivo models to study APC function and its implications for cancer therapy. She collaborates widely, particularly with Dr. Kathleen Goss, and her work includes data mining of patient datasets to correlate APC status with clinical outcomes.

Dr. Prosperi leads a dynamic research group focused on uncovering new therapeutic strategies for breast cancer, particularly in the context of APC-deficient tumors. Her lab integrates molecular biology, cell signaling, and pharmacological approaches to address key challenges in cancer treatment.